16-Jan-2008 - The Wellcome Trust

Novacta receives £3.5 million strategic translation award from the Wellcome trust ot target C. difficile infections

Novacta Biosystems, a UK-based anti-infective therapeutics company, announced that the Wellcome Trust, the UK's largest medical research charity, has awarded it £3.5 million as part of the Trust's Strategic Translational Award programme. Novacta will use the award to progress development of a drug which, it is hoped, will help combat hospital-based Clostridium difficile (C.difficile) infections.

Novacta is developing novel, naturally-derived products known as 'lantibiotics' as potential drugs for treating hospital acquired infections caused by C.difficile. Early preclinical data show promise for an effective treatment for CDI, acting selectively to kill C.difficile with less disturbance of normal gut bacteria than seen with existing drugs. Novacta will use the Wellcome Trust Strategic Translational award to progress its preclinical drug candidates into human clinical studies.

Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust, said "It is ironic that the current rise in C.difficile infections owes much to the widespread use of broad spectrum antibiotics. We need to be smarter in how we deploy our existing medicines and how we develop new treatments. Novacta should be applauded for its efforts to move away from carpet bombing our microbial flora in favour of precision targeting of the C.difficile bacterium."

Facts, background information, dossiers
More about Wellcome Trust
  • News

    Avilex Pharma receives Wellcome Trust Translation Award

    Avilex Pharma announces that it has received a 18 million DKK (2.4 million EUR) Translation Award from  Wellcome Trust to fund the development of a novel drug candidate for acute treatment of ischemic stroke. Ischemic stroke is a leading cause of death and disability worldwide, with very fe ... more

    Merck Serono to Collaborate With The Institute of Cancer Research, London, and Wellcome Trust

    Merck Serono, the biopharmaceutical division of Merck, The Institute of Cancer Research (ICR), and the Wellcome Trust, London, announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, ... more

    How DNA is ‘edited’ to correct genetic diseases

    An international team of scientists has made a major step forward in our understanding of how enzymes ‘edit’ genes, paving the way for correcting genetic diseases in patients. Researchers at the Universities of Bristol, Münster and the Lithuanian Institute of Biotechnology have observed the ... more

  • Associations

    The Wellcome Trust

    The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending around £650 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research an ... more